Secretory functions of the vascular endothelium

• Autorzy: Vane J R , Botting R.M.
• Języki publikacji: EN

Abstrakty

EN

The endothelial cells which line the blood vessels as a monolayer exert a remarkable control over the vascular system. Indeed, the endothelium can be regarded as a highly active metabolic and endocrine organ in its own right. On the hand, vasoactive substances such as serotonin and bradykinin are inactivated and on the other the cells can enzymatically produce the vasoconstrictor, angiotensin II and secrete endothelin-1 ((ET-1). Perhaps more importantly, the cells also produce two unstable vasodilator substances, which potently inhibit platelet clumping: prostacyclin and endothelium-derived relaxing factor (EDRF) which has been identified as nitric oxide (NO; 1). Both substances seem well designated as local hormones, released to influence adjacent cells. The endothelial cell, therefore, exerts control over the cardiovascular system by elaborating dilator substances as well as vasconstrictors.

Słowa kluczowe

EN

blood vessel; endothelial cell; nitric oxide; prostacyclin; cardiovascular system; endothelium; hormone

• Wydawca: -
• Czasopismo: Journal of Physiology and Pharmacology
• Rocznik: 1992
• Tom: 43
• Numer: 3
• Opis fizyczny: p.195-207

Twórcy

autor

Vane J R

• Hospital Medical College, Charterhouse Square, London EC1M 6BQ, U.K.

autor

Botting R.M.

Bibliografia

• 1. Palmer RMJ, Ferridge AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
• 2. Piper P, Vane JR. The release of prostaglandins from lung and other tissues. Ann NY Acad Sci 1971; 180:363-385.
• 3. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension 1988; 12:530-548.
• 4. Blair IA, Barrow SE, Waddell KA, Lewis PJ, Dollery CT. Prostacyclin is not a circulating hormone in man. Prostaglandins 1982; 23:579-589.
• 5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
• 6. Kanamaru K, Waga S, Kojuma T, Fujimoto K, Niwa S. Endothelium-dependent relaxation of canine basilar arteries. Part 2. Inhibition by hemoglobin and cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage. Stroke 1987; 18: 938-943.
• 7. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin requiring enzyme.Proc Natl Acad Sci USA 1990; 87:682-685.
• 8. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome. Nature 1991; 351:714-718.
• 9. Mitchell JA, Hecker M, Vane JR. The generation of L-arginine in endothelial cells is linked to the release of endothelium-derived relaxing factor. Eur J Pharmacol 1990; 176:253-254.
• 10. Hecker M, Mitchell JA, Harris HJ, Katsura M, Thiemermann C, Vane JR. Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun 1990; 167:1037-1043.
• 11. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitic oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989, 38:1709-1715.
• 12. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N. Engl J. Med 1990; 323:22-27.
• 13. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2:997-1000.
• 14. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregatory properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92:639-646.
• 15. De Nucci G, Gryglewski RJ, Warner TD, Vane JR. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85:2334-2338.
• 16. Salvemini D, de Nucci G, Gryglewski RJ, Vane JR. Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Sci USA 1989; 86:6328-6332.
• 17. Willis AL, Smith DL, Vigo C, Kluge AF. Effects of prostacyclin and orally active stable mimetic agent RS-93427-007 on basic mechanisms of atherogenesis. Lancet 1986; 2:682-683.
• 18. Dadak CH, Leithner C, Sinzinger H, Silberbauer K. Diminished prostacyclin formation in umbilical arteries of babies born to women who smoke. Lancet 1981; 1:94.
• 19. Ludmer PL, Selwyn AP, Shook PL. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315:1046-1051.
• 20. Fostermann U, Mugge A, Alheid U, Haverich U, Frolich JC. Selective attenuation of endothelium mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 1988; 62:185-190.
• 21. Jacobs M, Plane F, Bruckdorger KR. Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol 1990; 100:21-26.
• 22. Barret ML, Willis AL, Vane JR. Inhibition of platelet-derived mitogen release by nitric oxide (EDRF). Agents Actions 1989; 27:488-491.
• 23. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83:1774-1777.
• 24. Kilbourn RG, Gross SS, Jubran A et al. NG-methyl-Larginine inhibits tumour necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Aatl Acad Sci USA 1990; 87:3629-3632.
• 25. Adams LB, Hibbs JB, Taintor RR, Krahenbuhll JL. Microbiostatic effect of murine-activated macrophages for Toxoplasma gondii. J Immunol 1990; 144:2725-2729.
• 26. Li L, Kilbourn RG, Adams J, Fidler IJ. Role of nitric oxide in lysis of tumour cells by cytokine-uctivated endothelial cells. Cancer Res 1991; 51:2531-2535.
• 27. Longmore DB, Hoyle PM, Gregory A, et al. Prostacyclin administration during cardiopulmonary bypass in man. Lancet 1981; 2:800-804.
• 28. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary hypertension with intavenous epoprostenol (prostacyclin). Br Heart J 1987; 57: 270-278.
• 29. Yui Y, Nakajima H, Kawai H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 1982; 50:320-324.
• 30. Yardumian DA, Isenberg DA, et al. Successful treatment of Raynaud’s syndrome with iloprost,a chemically stable prostacyclin analogue. Br J Rheumatol 1988; 27:220-226.
• 31. Rademaker M, Cooke ED, Almond NE, et al. Comparison of intravenous infusions of iloprost and oral nitedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: double blind randomised study. Br J Med 1989; 298:561-564.
• 32. Feissinger JN, Schafer M, Angelides NS. For the TAO Studa. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangitis obliterans. Lancet 1990; 335:55-557.
• 33. Sturzebecher S, Hildebrand M, Schobel C,Scifert W, Staks T. Platelet inhibitory and haemodynamic effects of a new stable PGI₂ analogue, cicaprost (ZK 96480), in different animal species and in man. Biomed Biochim Acta 1988; 47:S45-S47.
• 34. Korbut R, Lidbury PS, Vane JR. Prolongation of fibrinolytic ativity of tissue plasminogen activator by nitro vasodilators. Lancet 1990; 335:669.
• 35. Rubanyi GM. Endothelium-derived vasconstictor factor. In Endothelial cells, Vol 3, US Ryan (ed.) Florida, CRC Press, Boca Raton, 1988, pp. 61-74.
• 36. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
• 37. Landan G, Bdolah A, Wollberg Z, Kochva E, Graur D. Evolution of the sarafotoxin/endothelin superfamily of proteins. Toxicon 1987; 29:237-244.
• 38. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 1989; 161:562-567.
• 39. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991; 174:613-618.
• 40. McMahon EG, Palomo MA, Moore WM. Phosphoramidon blocks the pressor activity of big endothelin [1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1991; 17 (Suppl. 7) 529-533.
• 41. Miyauchi T, Yanagisawa M, Tomizawa T, et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989; 2:53-54.
• 42. Kashiwabara T, Inagaki Y, Ohta H, et al. Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo. FEBS Lett 1989; 247:73-746.
• 43. Pernow J, Franco-Cereda A, Matran R, Lundberg JM. Effect of endothelin-1 on regional vascular resistances in the pig. J Cardiovasc Pharmacol 1989; 13 (Suppl 5):S205-S206.
• 44. Anggard E, Galton S, Rae G, et al. The fate of radioiodinated endothelin-1 and endothelin-3 in the rat. J Cardiovasc Pharmacol 1989; 13 (Suppl 5):S46-S49.
• 45. Brain SD, Crossman DC, Buckley TL, Williams TJ. Endothelin-1: demonstration of potent effects on the microcirculation of human and other species. J Cardiovasc Pharmacol 1989; 13 (Suppl 5):S147-S149.
• 46. Matsumura Y, Makase K, Ikegawa R, Hayashi K, Ohyama T, Morimoto S. The endothelium-derived vasoconstrictor peptide endothelin inhibits renin release in vitro. Life Sci 1989; 44:149-157.
• 47. Miller WL, Redfield MM, Burnett Jr JC. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest 1989; 83:317-320.
• 48. Kohno M, Yasunari K, Murakawa K-I et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88:614-618.
• 49. Saito Y, Nakao K, Yamada T et al. Plasma endothelin 1-like immunoreactivity level (ET-l-LI) in healthy subjects and patients with hypertension. Hypertension 1989; 14:335-336 (abstract).
• 50. Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest 1989; 84:1032-1035.
• 51. Boarder MR, Marriott DB. Characterization of endothelin-1 stimulation of catecholamine release from adrenal chromaffin cells. J Cardiovasc Pharmacol 1989; 13 (Suppl. 5): S223-S224.
• 52. Tomobe Y, Miyauchi T, Saito A et al. Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats. Eur J Pharmacol 1988; 152:373-374.
• 53. Firth JD, Raine AEG, Ratcliffe, PJ Ledingham JGG. Endothelin: an important factor in renal failure? Lancet 1988, 2:1179-1182.
• 54. Tomita K, Ujlie, K, Nakanishi T et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 321:1127.
• 55. Kosaka T, Suzuki N, Matsumoto H et al. Synthesis of the vasconstrictor peptide endothelin in kidney cells. FEBS Lett 1989; 249:42-46.
• 56. Berbinschi A, Ketelslegers J. Endothelin in urine. Lancet 1989; 2:46.
• 57. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85:587-590.
• 58. Nakamura T, Kasai K, Konuma S et al. Immunoreactive endothelin concentrations in maternal and fetal blood. Life Sci 1990; 46:1045-1050.
• 59. De Nucci G, Thomas R, D’Orleans-Juste P et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85:9797 -9800.
• 60. Walder C, Thomas R, Thiemermann C, Vane JR. The haemodynamic effects of endothelin-1 in the pithed rat. J Cardiovasc Pharmacol 1989; 13 (Suppl. 5):S93-S97.
• 61. Thiemermann C, Lidbury PS, Thomas GR, Vane JR. Comparison of the haemodynamic and platelet inhibitory effects of endothelin-1 and endothelin-3 in the anaesthetized rabbit. In Endothelium-derived Contracting Factors Rubanyi GM, Vanhoutte PM (eds) Basel, Kargel 1990; pp. 128-134.
• 62. Whittle BJR, Lopez-Belmonte J, Rees DD. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol 1989; 98:646-652.
• 63. Gardiner SM, Compton AM, Bennett T, Palmer RMJ, Moncada S. The effects of NG-monomethyl-Larginine (L-NMMA) on the haemodynamic actions of endothelin-1 in conscious Long Evans rats. Br J Pharmacol. 1989; 98:626P.
• 64. Karwatowska-Prokopczuk E, Wennmalm A. Effects of endothelin on coronary flow, mechanical performance, oxygen uptake and formation of purines and on outflow of prostacyclin in isolated rabbit heart Circ Res 66:46-54.
• 65. Trybulec M, Dudek RR, Gryglewski RJ. Effects of endothelin-1 and endothelin-3 on the release of prostanoids from isolated perfused rat kidney. J Cardiovasc Pharmacol 1991; 17 (Suppl. 7):S229-S232.
• 66. Warner TD, Mitchell JA, de Nucci G, Vane JR. Endothelin-1 and endothelin-3 release EDRF from isolated perfused arterial vessels of the rat and rabbit. J Cardiovasc Pharmacol 1989; 13 (Suppl. 5):S85-S88.
• 67. Fukuda N, Izumi Y, Soma M et al. L-NG-monomethyl arginine inhibits the vasodilating effects of low dose of endothelin-3 on rat mesenteric arteries. Biochem Biophys Res Commun 1990; 167:739-745.
• 68. Thiemermann C, Lidbury PS, Thomas GR, Vane JR. Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anaesthetized rabbit. J Cardiovasc Pharmacol 1989; 13 (Suppl. 5):S138-S141.
• 69. Herman F, Magyar K, Chabrier P-E, Braquet P, Filep J. Prostacyclin mediates antiaggregatory and hypotensive actions of endothelin in anaesthetized beagle dogs. Br J Pharmacol 1989; 98:38-40.
• 70. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986; 88:411-415.
• 71. Thiemermann C, May GR, Page CP, Vane JR. Endothelin-1 inhibits platelet aggregation in vivo: a study with ¹¹¹ lundium-labelled platelets. Br J Pharmacol 1990; 99:303-308.
• 72. Lin HY, Kaji EH, Winkel GK, Ives HE, Lodish HF. Cloning and functional expression of a vascular smooth muscle endothelin vl receptor. Proc Natl Acad Sci USA 1991; 88:3185-3189.
• 73. Sakurai T, Yanagisawa M, Takuwa Y et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348:732-735.
• 74. Lidbury PS, Thiemermann C, Korbut R, Vane JR. Endothelins release tissue plasminogen activator and prostanoids. Eur J Pharmacol 1990; 186:205-212.
• 75. Korbut R, Lidbury PS, Thomas GR, Vane JR. Fibrinolytic activity of endothelin-3. Thromb Res 1989; 55:797-799.